Latest Cormorant Asset Management, LP Stock Portfolio
Cormorant Asset Management, LP Performance:
2025 Q1: -18.89%YTD: -18.89%2024: 5.9%
Performance for 2025 Q1 is -18.89%, and YTD is -18.89%, and 2024 is 5.9%.
About Cormorant Asset Management, LP and 13F Hedge Fund Stock Holdings
Cormorant Asset Management, LP is a hedge fund based in BOSTON, MA. On 31-Mar-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $3.1 Billions. In it's latest 13F Holdings report, Cormorant Asset Management, LP reported an equity portfolio of $1.3 Billions as of 31 Mar, 2025.
The top stock holdings of Cormorant Asset Management, LP are MLTX, EWTX, BBIO. The fund has invested 25% of it's portfolio in MOONLAKE IMMUNOTHERAPEUTICS and 6.8% of portfolio in EDGEWISE THERAPEUTICS INC.
The fund managers got completely rid off ARRIVENT BIOPHARMA INC, IMMUNITYBIO INC (IBRX) and VYNE THERAPEUTICS INC (VYNE) stocks. They significantly reduced their stock positions in BIOHAVEN LTD, RHYTHM PHARMACEUTICALS INC (RYTM) and AVIDITY BIOSCIENCES INC (RNA). Cormorant Asset Management, LP opened new stock positions in METSERA INC and PLIANT THERAPEUTICS INC (PLRX). The fund showed a lot of confidence in some stocks as they added substantially to GH RESEARCH PLC, ARS PHARMACEUTICALS INC (SBTX) and BRIDGEBIO PHARMA INC (BBIO).
The top stock holdings of Cormorant Asset Management, LP are MLTX, EWTX, BBIO. The fund has invested 25% of it's portfolio in MOONLAKE IMMUNOTHERAPEUTICS and 6.8% of portfolio in EDGEWISE THERAPEUTICS INC.
The fund managers got completely rid off ARRIVENT BIOPHARMA INC, IMMUNITYBIO INC (IBRX) and VYNE THERAPEUTICS INC (VYNE) stocks. They significantly reduced their stock positions in BIOHAVEN LTD, RHYTHM PHARMACEUTICALS INC (RYTM) and AVIDITY BIOSCIENCES INC (RNA). Cormorant Asset Management, LP opened new stock positions in METSERA INC and PLIANT THERAPEUTICS INC (PLRX). The fund showed a lot of confidence in some stocks as they added substantially to GH RESEARCH PLC, ARS PHARMACEUTICALS INC (SBTX) and BRIDGEBIO PHARMA INC (BBIO).
Cormorant Asset Management, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Cormorant Asset Management, LP made a return of -18.89% in the last quarter. In trailing 12 months, it's portfolio return was -19.07%.
New Buys
| Ticker | $ Bought |
|---|---|
| metsera inc | 10,888,000 |
| korro bio inc | 6,621,080 |
| aardvark therapeutics inc | 6,009,420 |
| pliant therapeutics inc | 4,050,000 |
New stocks bought by Cormorant Asset Management, LP
Additions
| Ticker | % Inc. |
|---|---|
| gh research plc | 238 |
| ars pharmaceuticals inc | 220 |
| cargo therapeutics inc | 185 |
| bridgebio pharma inc | 25.00 |
| edgewise therapeutics inc | 20.42 |
| praxis precision medicines i | 3.06 |
Additions to existing portfolio by Cormorant Asset Management, LP
Reductions
| Ticker | % Reduced |
|---|---|
| biohaven ltd | -81.99 |
| rhythm pharmaceuticals inc | -62.5 |
| avidity biosciences inc | -61.9 |
| vaxcyte inc | -58.82 |
| crinetics pharmaceuticals in | -40.00 |
| arcutis biotherapeutics inc | -26.03 |
| axsome therapeutics inc | -23.08 |
| tarsus pharmaceuticals inc | -20.00 |
Cormorant Asset Management, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| immunitybio inc | -7,680,000 |
| vyne therapeutics inc | -4,671,030 |
| arrivent biopharma inc | -15,596,700 |
| septerna inc | -12,824,000 |
| y-mabs therapeutics inc | -3,327,750 |
| verve therapeutics inc | -1,974,000 |
| omeros corp | -2,964,000 |
| urogen pharma ltd | -3,195,000 |
Cormorant Asset Management, LP got rid off the above stocks
Sector Distribution
Cormorant Asset Management, LP has about 78.3% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 78.3 |
| Others | 20.2 |
| 1.5 |
Market Cap. Distribution
Cormorant Asset Management, LP has about 3% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 47.8 |
| UNALLOCATED | 24.6 |
| SMALL-CAP | 23.8 |
| LARGE-CAP | 3 |
Stocks belong to which Index?
About 37.7% of the stocks held by Cormorant Asset Management, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 62.3 |
| RUSSELL 2000 | 37.7 |
Cormorant Asset Management, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Cormorant Asset Management, LP
Cormorant Asset Management, LP has 42 stocks in it's portfolio. About 64.8% of the portfolio is in top 10 stocks. MLTX proved to be the most loss making stock for the portfolio. BBIO was the most profitable stock for Cormorant Asset Management, LP last quarter.
Last Reported on: 15 May, 2025| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 5.18 | 1,050,000 | 68,880,000 | reduced | -19.23 | ||
| ARQT | arcutis biotherapeutics inc | 1.59 | 1,350,000 | 21,114,000 | reduced | -26.03 | ||
| AXSM | axsome therapeutics inc | 2.19 | 250,000 | 29,157,500 | reduced | -23.08 | ||
| BBIO | bridgebio pharma inc | 5.20 | 2,000,000 | 69,140,000 | added | 25.00 | ||
| BMEA | biomea fusion inc | 0.57 | 3,570,870 | 7,605,960 | unchanged | 0.00 | ||
| CNTA | centessa pharmaceuticals plc | 2.44 | 2,261,600 | 32,521,800 | reduced | -11.71 | ||
| CRBP | corbus pharmaceuticals hldgs | 0.95 | 2,375,000 | 12,611,200 | unchanged | 0.00 | ||
| CRNX | crinetics pharmaceuticals in | 1.51 | 600,000 | 20,124,000 | reduced | -40.00 | ||
| EWTX | edgewise therapeutics inc | 6.79 | 4,101,990 | 90,243,800 | added | 20.42 | ||
| EYPT | eyepoint pharmaceuticals inc | 3.39 | 8,325,000 | 45,121,500 | unchanged | 0.00 | ||
| IBRX | immunitybio inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| INSM | insmed inc | 3.01 | 525,000 | 40,052,200 | reduced | -19.23 | ||
| JANX | janux therapeutics inc | 4.06 | 2,000,000 | 54,000,000 | reduced | -4.76 | ||
| KALA | kala bio inc | 0.26 | 603,027 | 3,455,340 | unchanged | 0.00 | ||
| MLTX | moonlake immunotherapeutics | 24.95 | 8,494,150 | 331,866,000 | unchanged | 0.00 | ||
| MRUS | merus n v | 2.34 | 740,000 | 31,146,600 | unchanged | 0.00 | ||
| NAMS | newamsterdam pharma company | 4.35 | 2,825,000 | 57,827,800 | reduced | -13.08 | ||
| OMER | omeros corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PCVX | vaxcyte inc | 0.50 | 175,000 | 6,608,000 | reduced | -58.82 | ||
| PHVS | pharvaris n v | 1.73 | 1,466,460 | 23,023,400 | unchanged | 0.00 | ||